crc-23-0072_fig1.png (185.46 kB)

FIGURE 1 from Salvage Ipilimumab plus Nivolumab after Anti-PD-1/PD-L1 Therapy in Advanced Hepatocellular Carcinoma

figure

posted on 2023-07-20, 02:20 authored by Stephanie L. Alden, Mir Lim, Chester Kao, Daniel Shu, Amit G. Singal, Anne Noonan, Paige Griffith, Marina Baretti, Won Jin Ho, Ihab Kamel, Mark Yarchoan, David Hsiehchen

Target lesion change and objective response. Percent change in patient target lesion(s), determined by investigator review of pretreatment and posttreatment imaging, with BOR using criteria from RECIST v1.1. BOR, best overall response; CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease.

Funding

HHS | National Institutes of Health (NIH)

HHS | NIH | National Cancer Institute (NCI)

Cancer Prevention and Research Institute of Texas (CPRIT)

History

ARTICLE ABSTRACT

Anti-PD-(L)1 containing regimens are the preferred first-line treatment for advanced HCC, but whether salvage with PD-(L)1/CTLA-4 blockade is effective in patients who have failed prior anti-PD-(L)1 therapy is unknown. Our study demonstrates that ipilimumab plus nivolumab has clinical activity in patients with advanced HCC previously treated with anti-PD-(L)1 therapy, supporting the continued use of this regimen in the late-line setting after prior anti-PD-(L)1 exposure.

Usage metrics

Keywords

Clinical-Stage Research Immunotherapy Checkpoint blockade Gastrointestinal Cancers Liver cancer

Licence

CC BY

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM